1 / 32

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Stay updated with the latest advancements in high-risk dyslipidemia treatments. Explore the impact of ApoB/ApoA1 ratio, statins, LDL-C lowering efficacy, lipid goal attainment, PCSK9 inhibition, and CV outcomes trials. Learn about the FOURIER, EBINGHAUS, SPIRE-1, SPIRE-2, and ODYSSEY trials.

aronnie
Download Presentation

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

  2. Risk of MI Associated With ApoB/ApoA1 Ratio

  3. StatinsApproximate LDL-C-Lowering Efficacy

  4. Effect of Statins vs Placebo on CV Events

  5. Lipid Goal Attainment in Asian Patients With ACS

  6. PCSK9 Inhibition in Patients With Hypercholesterolemia Receiving Statin Therapy

  7. PCSK9 CV Outcomes Trials

  8. FOURIER Trial Design

  9. FOURIER Endpoints

  10. FOURIER Follow-Up

  11. FOURIER: Baseline Characteristics

  12. FOURIER: Lipid-Lowering Therapy and Lipid Levels at Baseline

  13. FOURIER: Effect on LDL-C

  14. FOURIER: Main CV Outcomes

  15. FOURIER: Main CV Outcomes (cont)

  16. FOURIER: Lower LDL-C Is Better

  17. FOURIER: Safety

  18. Summary of FOURIER

  19. EBINGHAUS: Trial Design

  20. Cognition and PCSK9 Inhibitors

  21. EBINGHAUS Primary Endpoint: Spatial Working Memory Strategy Index

  22. EBINGHAUS:Cognitive Assessments by Nadir Achieved LDL-C and Treatment

  23. The SPIRE-1 and SPIRE-2 CV Outcome Trials

  24. SPIRE-1 and SPIRE-2:Baseline Clinical Characteristics

  25. SPIRE-1 and SPIRE-2: Confirmation of Attenuation in LDL-C Reduction Over Time

  26. SPIRE-1 and SPIRE-2 Primary Prespecified Endpoint

  27. SPIRE-1 and SPIRE-2: Incidence Rates of AEs per 100 P-Y of Exposure

  28. ODYSSEY OutcomesPhase 3 Post-ACS With Alirocumab

  29. PCSK9 CV Outcomes Trials

  30. Abbreviations

  31. Abbreviations (cont)

  32. Abbreviations (cont)

More Related